Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial

Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH1 and TH17 responses and are implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA.

Source: Seminars in Arthritis and Rheumatism - April 21, 2018 Category: Rheumatology Authors: Richard Conway, Lorraine O ’Neill, Phil Gallagher, Geraldine M. McCarthy, Conor C. Murphy, Douglas J. Veale, Ursula Fearon, Eamonn S. Molloy Source Type: research